Evidence map›Paper›PMID 25839776›Full record

ArticleInflammatory bowel diseases2015

Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis.

Aaron T Sin, Jennifer L Damman, David A Ziring, Elizabeth E Gleghorn, Manuel G Garcia-Careaga, Roberto R Gugig, Anna K Hunter, Jennifer C Burgis, Dorsey M Bass, K T Park

Open access · bronzeAbstract read
In one paragraph

Article in Inflammatory bowel diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.Journal of the Canadian Association of Gastroenterology · 2019
    Article
  16. Review
  17. Proton Pump Inhibitors, HThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Aaron T Sin*School of Medicine, Stanford University, Palo Alto, California; †Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Oakland Children's Hospital, Oakland, California; ‡Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Mattel Children's Hospital, University of California Los Angeles, Los Angeles, California; §Department of Pediatrics, Division of Gastroenterology, Santa Clara Valley Medical Center, San Jose, California; ‖Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Lucile Packard Children's Hospital, Stanford University, Palo Alto, California; and ¶Department of Pediatrics, Division of Gastroenterology, Children's Hospital Central California, Madera, California; **Department of Pediatrics, Division of Gastroenterology and Nutrition, California Pacific Medical Center, San Francisco, California.
Jennifer L Damman
David A Ziring
Elizabeth E Gleghorn
Manuel G Garcia-Careaga
Roberto R Gugig
Anna K Hunter
Jennifer C Burgis
Dorsey M Bass
K T Park
Stanford University · USChildren's Hospital Central California · USCalifornia Pacific Medical Center · USUniversity of California, Los Angeles · US

Funding

Pharmaco-economics and Optimal Strategies of Biologics Use in Inflammatory BowelK08DK094868 · NIDDK · STANFORD UNIVERSITY · PI PARK, KT · 2012 to 2016
$769k
NIDDK NIH HHS K08 DK094868NIDDK NIH HHS K08 DK094868A
6 · The paper itself

Abstract

backgroundPediatric inflammatory bowel disease (IBD), consisting of Crohn's disease (CD) and ulcerative colitis (UC), can result in significant morbidity requiring frequent health care utilization. Although it is known that the overall financial impact of pediatric IBD is significant, the direct out-of-pocket (OOP) cost burden on the parents of children with IBD has not been explored. We hypothesized that affected children with a more relapsing disease course and families in lower income strata, ineligible for need-based assistance programs, disparately absorb ongoing financial stress.

methodsWe completed a cross-sectional analysis among parents of children with IBD residing in California using an online HIPAA-secure Qualtrics survey. Multicenter recruitment occurred between December 4, 2013 and September 18, 2014 at the point-of-care from site investigators, informational flyers distributed at regional CCFA conferences, and social media campaigns equally targeting Northern, Central, and Southern California. IBD-, patient-, and family-specific information were collected from the parents of pediatric patients with IBD patients younger than 18 years of age at time of study, carry a confirmed diagnosis of CD or UC, reside in and receive pediatric gastroenterology care in California, and do not have other chronic diseases requiring ongoing medical care.

resultsWe collected 150 unique surveys from parents of children with IBD (67 CD; 83 UC). The median patient age was 14 years for both CD and UC, with an overall 3.7 years (SD 2.8 yr) difference between survey completion and time of IBD diagnosis. Annually, 63.6%, 28.6%, and 5.3% of families had an OOP cost burden >$500, >$1000, and >5000, respectively. Approximately one-third (36.0%) of patients had emergency department (ED) visits over the past year, with 59.2% of these patients spending >$500 on emergency department copays, including 11.1% who spent >$5000. Although 43.3% contributed <$500 on procedure and test costs, 20.0% spent >$2000 in the past year. Families with household income between $50,000 and $100,000 had a statistically significant probability (80.6%) of higher annual OOP costs than families with lower income <$50,000 (20.0%; P < 0.0001) or higher income >$100,000 (64.6%; P < 0.05). Multivariate analysis revealed that clinical variables associated with uncontrolled IBD states correlated to higher OOP cost burden. Annual OOP costs were more likely to be >$500 among patients who had increased spending on procedures and tests (odds ratio [OR], 5.63; 95% confidence interval [CI], 2.73-11.63), prednisone course required over the past year (OR, 3.19; 95% CI, 1.02-9.92), at least 1 emergency department visit for IBD symptoms (OR, 2.84; 95% CI, 1.33-6.06), at least 4 or more outpatient primary medical doctor visits for IBD symptoms (OR, 2.82; 95% CI, 1.40-5.68), and history of 4 or more lifetime hospitalizations for acute IBD care (OR, 2.60; 95% CI, 1.13-5.96).

conclusionsPreviously undocumented, a high proportion of pediatric IBD families incur substantial OOP cost burden. Patients who are frequently in relapsing and uncontrolled IBD states require more acute care services and sustain higher OOP cost burden. Lower middle income parents of children with IBD ineligible for need-based assistance may be particularly at risk for financial stress from OOP costs related to ongoing medical care.

Indexed as

Cost of IllnessAdolescentCaliforniaChildCohort StudiesColitis, UlcerativeCrohn DiseaseCross-Sectional StudiesEmergency Service, HospitalFinancing, PersonalHealth Care SurveysHospitalizationHumansOffice VisitsParentsSocioeconomic Factors

Identifiers

PMID25839776
PMCPMC4437842
OpenAlexW1977899305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.